Low-molecular-mass neutrophil elastase inhibitors have been shown to be important in the control of lung inflammation. In addition to inhibiting the enzyme neutrophil elastase, these low-molecular-mass compounds (1 0 kDa) have been shown to have other activities. For example, secretory leucocyte proteinase inhibitor (SLPI) and elastase-specific inhibitor/SKALP (skinderived antileucoproteinase)/elafin have also been shown to have ' defensin '-like antimicrobial
1 1 1 activities. Indeed, these inhibitors have antimicrobial properties in vitro against bacteria, fungi and, potentially, HIV. In addition, we have shown, using an adenovirus-mediated gene transfer overexpression strategy, that elafin is also active against Pseudomonas aeruginosa infection in mice in uivo. T h e mechanism of action is currently under investigation. In addition to these direct or indirect effects on microbes, it has been shown that lipopolysaccharide is able to up-regulate SPLI production in macrophages in vitro, and that the addition of recombinant SLPI to human monocytes or the transfection of macrophages with SPLI can down-regulate pro-inflammatory mediators such as tumour necrosis factor, presumably to limit self-damaging excessive inflammation. Using viral gene transfer vectors, we are currently investigating the potential of these inhibitors in various models of inflammation in vzuo.
Introduction
Antiproteinases are important molecules that are involved in the acute-phase response (APR), which is the response of the body to the initiation and development of inflammation. T h e APR [l J is a very tightly regulated process which is initiated locally by inflammatory cells (such as monocytes, macrophages and neutrophils). These cells secrete products (cytokines) which in turn act at distant sites such as the liver, which is mainly responsible for switching on the APR. Antiproteinase molecules are produced either locally at mucosal sites or systemically by the liver. Their primary function was thought until recently to be the prevention of the potential injurious effects of excess release of proteolytic enzymes from inflammatory cells. However, recently, new potential functions have been ascribed to these antiproteinases.
These molecules seem to have developed in a parallel network, consisting of 'alarm' and 'systemic' inhibitors [2] . T h e first group is composed of secretory leucocyte proteinase inhibitor (SLPI) (also known as antileucoproteinase, mucus proteinase inhibitor or bronchial inhibitor; this inhibitor will henceforth be referred to as SLPI) and of the elastase-specific inhibitor, also known as elafin or skin-derived antileucoproteinase (SKALP) [3]. These molecules are synthesized and secreted locally at the site of injury. Interestingly, these molecules are produced in response to ' first-wave ' cytokines, such as interleukin-1 (IL-1) and tumour necrosis factor (TNF), and might therefore be part of a first wave of local, inducible defence by the antiproteinase network. T h e concentration of these inhibitors is very low in the circulation [4,5] and they are not expressed in liver cells [6, 7] . T h e second group is composed of systemic antiproteinases such as a,-antichymotrypsin and a,-proteinase inhibitor (a,-Pi), which are produced in abundance by the liver and secreted in high concentrations in the circulation as acute-phase reactants [8] . T h e liver produces these systemic antiproteinases in response to 'secondary' cytokines, such as members of the IL-6 family, including IL-6 itself, leukaemia inhibitory factor and oncostatin M [l] .
SLPI
Structure and function SLPI is one of the two members of the antileucoproteinase superfamily of proteinase inhibitors (the other being elastase-specific inhibitor/elafin/ SKALP; see below). T h e SLPI gene (2.65 kb in length [9, 10] ) is a non-polymorphic, stable gene that can be modulated at both the transcriptional and translational levels [ll] . It is an 11.7 kDa protein, consisting of 107 amino acids and comprising two domains. It contains 16 cysteine residues, which form eight disulphide bridges. SLPI has been shown to inhibit human neutrophil elastase, cathepsin G, trypsin, chymotrypsin and chymase. Its major target is thought to be human neutrophil elastase, in view of its high affinity and kinetic constants ( K , in the nanomolar range and k , , in the micromolar range) [12] .
Cellular and histological distribution
SLPI is a molecule that is present constitutively in most mucosal sites (hence its alternative name mucus proteinase inhibitor). In lung tissues, it is produced in vitro by tracheal, bronchial, bronchiolar and type I1 alveolar cells, as well as by monocytes, alveolar macrophages and neutrophils [13, 14] . It has also been shown to be produced in vivo by tracheal serous glands and bronchiolar Clara cells, and to be closely associated with elastin fibres in the alveolar interstitium [13] . Its roles in inflammatory cells, such as macrophages or neutrophils, are uncertain, but antibacterial or antiinflammatory actions have been proposed (see below).
Elastase-specific inhibitodelafin/ SKALP
Structure and function T h e neutrophil elastase inhibitor elafin (the other member of the antileucoproteinase superfamily of proteinase inhibitors; for a recent review, see [15] ) was first identified as a 'non-SLPI' lowmolecular-mass anti-elastase by Hochstrasser 
Role of antiproteinases in innate immunity
Antiproteinases such as a,-proteinase inhibitor and the low-molecular-mass proteinase SLPI have recently been hypothesized to also be important in the regulation of innate immunity and in the control of excessive inflammation and septic shock. Indeed, a,-proteinase inhibitor has been shown to inhibit lethality in mice challenged with LPS and TNF, supporting the notion that the action of this proteinase inhibitor may be in prevention of the release of membrane-bound T N F [36, 37] . It has also been shown in vitro that LPS is able to up-regulate SLPI production in macrophages [25] (which in turn is able to bind to LPS 
Direct antimicrobial activities
In addition to their elastase-inhibitory properties, which were identified first (see above), and because of their biochemical characteristics (lowmolecular-mass cationic peptides, heavily disulphide-bonded, present at mucosal sites), SLPI and elafin may also have direct antimicrobial activities, and may be good candidates as 'defen- T h e mechanism of the protection conferred by elafin in this model is still under investigation, but does not seem to involve its antiproteinase activity directly, since elafin contributed to less than 0.1 % of the anti-elastase activity. Interestingly, a similar effect was noted by Cantin and Woods [45] in a rat model. I t was noted that intra-
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tracheal administration of a,-proteinase inhibitor protein was also protective against P. aeruginosa.
Therapeutic options and gene therapy
Although still in its infancy compared with pharmacological methods of drug delivery, gene therapy, because of its less transient nature, might be advantageous. Indeed, adenovirus could be the vector of choice for many gene therapy applications. Although, historically, most of these applications have been directed to chronic pathologies such as cystic fibrosis and cancer, success has recently been achieved in animal models of lung infections and endotoxaemia in rodents using adenovirus vectors. In these studies, transgenes coded for molecules involved either in the priming of innate immunity [46,47] or in direct antimicrobial activities [44,48]. Because of the aforementioned characteristics of SLPI and elafin as 'alarm molecules' involved in the regulation of early events in the inflammatory process, overexpression of these proteinase inhibitors may be of benefit in combatting bacterial infections and their inflammatory sequelae.
Conclusion
Proteinase inhibitors form part of a major family of proteins (acute-phase proteins) that are upregulated either locally at mucosal tissues or systemically in the liver. Given their primary antienzymic properties, it was originally believed that the organism requires increased levels of these proteins to combat proteinases secreted in excess, either by invading micro-organisms or by the host itself.
Although this may still hold true, novel functions for proteinase inhibitors have recently emerged in relation to their role in innate immunity. These functions encompass direct antimicrobial activities against viruses and bacteria, as well as possible bacterial LPS-modulating activities. These latter activities may be of particular importance in pathophysiology and are the focus of our current work on the use of gene therapy vectors for antiproteinase augmentation. Translating these findings into the clinic and identifying the best vector for administration and the cohort of patients most likely to benefit will remain, undoubtedly, a major focus of studies in the foreseeable future.
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